Research Summary: Capivasertib is a potent, selective inhibitor of all three protein kinase B (AKT1/2/3) isoforms. The phosphoinositide 3- kinase/protein kinase B pathway
Research Summary: Covalent Bruton tyrosine kinase (BTK) inhibitors have become the preferred treatment for chronic lymphocytic leukemia (CLL). However, the first-generation BTK inhibitor
Research Summary: Accurate prognostic assessment in patients with cutaneous melanoma is essential as it is one of the most prevalent malignancies in the
Research Summary: Cutaneous melanoma is a significant public health concern, as it is the fifth most common cancer in the United States. Traditional
Research Summary: Estrogen receptor–positive (ER+) breast cancer is primarily driven by signaling through estrogen receptor α, a nuclear hormone receptor that regulates transcriptional
Research Summary: Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CAR-T) therapy that has transformed outcomes for patients
Research Summary: The EMBER-3 trial1 was a Phase III, open-label study that evaluated imlunestrant, a next-generation oral selective estrogen-receptor degrader (SERD) with brain-penetrant
Research Summary: For patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM), prior reports have shown median progression-free survival (PFS) of less than six
Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is typically administered in the inpatient setting, but accessibility to outpatient administration is expanding. Benefits
Research Summary This study1 evaluated the Medicare cost impact of choosing among covalent Bruton tyrosine kinase inhibitors (cBTKis) for treatment-naïve (TN) and relapsed/refractory
Research Summary In this randomized, controlled, Phase III study,1 patients with resectable, epidermal growth factor receptor (EGFR)–mutated, Stage II to IIIB non-small cell
Research Summary Advances in T-cell redirecting therapy (TCRT), which includes chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engagers (TCEs), have favorably
Research Summary Ciltacabtagene autoleucel (cilta-cel) is a second-generation autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA) on the
The phosphoinositide 3-kinase (PI3K)-AKT signaling pathway is a key regulator of cell growth, survival, and metabolism and is frequently altered in estrogen receptor–positive
Research Summary Bruton tyrosine kinase (BTK) inhibitors have improved the treatment landscape of chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation, highly selective,
Research Summary Concurrent chemoradiotherapy (cCRT) followed by adjuvant durvalumab is the standard first-line treatment for patients with unresectable Stage III non-small cell lung
Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is an effective treatment option for relapsed/refractory multiple myeloma (RRMM). Nurses play a crucial role
Research Summary: Sentinel lymph node biopsy (SLNB) is a standard procedure for staging and management in patients with cutaneous melanoma, aimed at assessing
Research Summary For patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), EGFR-tyrosine kinase inhibitors (TKIs) can be used as
Treatment with a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, such as abemaciclib, plus (+) endocrine therapy (ET) has been shown to improve survival
©2026 Oncology Matrix. All Rights Reserved.
